Paul Janssen

Last updated

Paul Adriaan Jan Janssen
Beerse Statue Paul Janssen 070225.JPG
Statue of Janssen in Beerse, Belgium
Born12 September 1926
Died11 November 2003(2003-11-11) (aged 77)
Nationality Belgian
Education Université de Namur
Catholic University of Louvain
Ghent University
University of Cologne
Occupation(s)Physician
Founder, Janssen Pharmaceutica
SpouseDora Arts
Parent(s) Constant Janssen
Margriet Fleerackers

Paul Adriaan Jan, Baron Janssen (12 September 1926 – 11 November 2003) was a Belgian physician. He was the founder of Janssen Pharmaceutica, a pharmaceutical company with over 20,000 employees [1] which is now a subsidiary of Johnson & Johnson.

Contents

Early life and education

Paul Janssen was the son of Constant Janssen and Margriet Fleerackers.

He attended secondary school at the Jesuit St Jozef college in Turnhout, Belgium after which he decided to follow in his father's footsteps and become a physician. During World War II Janssen studied physics, biology and chemistry at the Facultés universitaires Notre-Dame de la Paix (FUNDP) in Namur. He then studied medicine at the Catholic University of Leuven and Ghent University. In 1951, Janssen received his medical degree magna cum laude from Ghent University. [2] He graduated with a postdoctoral degree in pharmacology at the same university in 1956, and studied at the Institute of Pharmacology of the University of Cologne. [3]

On 16 April 1957, he married Dora Arts.

Career

During his military service and until 1952, he worked at the Institute of Pharmacology of the University of Cologne. After he returned to Belgium, he worked part time at the University of Ghent Institute of Pharmacology and Therapeutics, headed by Corneille Heymans, who had won the Nobel Prize for medicine in 1938.[ citation needed ]

With a loan of fifty thousand Belgian francs received from his father, Janssen founded his own research laboratory in 1953. That same year, he discovered ambucetamide, an antispasmodic found to be particularly effective for the relief of menstrual pain. [4]

In 1956, Janssen received his habilitation in pharmacology with pro venia legendi ("permission to lecture") designation for his thesis on Compounds of the R 79 type. He left the university and established what would become Janssen Pharmaceutica.[ citation needed ]

On 11 February 1958 he developed haloperidol, a major breakthrough in the treatment of schizophrenia. [5] Working with his team, he developed the fentanyl family of drugs and a number of anesthetic agents, including droperidol and etomidate. [6] [7] One of the anti-diarrheal drugs he developed, diphenoxylate (Lomotil), was used in the Apollo program. [8] [9]

In 1985, Janssen Pharmaceutical became the first Western pharmaceutical company to establish a factory in the People's Republic of China (Xi'an). [10] In 1995, together with Paul Lewi, he founded the Center for Molecular Design, where he and his team [11] used a supercomputer to search candidate molecules for potential AIDS treatments. [12] [13]

Altogether Janssen and his cadre of scientists discovered more than eighty new medications, four of which are on the WHO list of essential medicines.[ citation needed ]

In 1991, he was elevated to the Belgian nobility by King Baudouin receiving the title of Baron .[ citation needed ]

Death

Janssen died in Rome in 2003, while attending the celebration of the 400th anniversary of the founding of the Pontifical Academy of Sciences, of which he had been a member since 1990. [14]

Popularity polls

See also

Related Research Articles

<span class="mw-page-title-main">Ketanserin</span> Antihypertensive agent

Ketanserin (INN, USAN, BAN) (brand name Sufrexal; former developmental code name R41468) is a drug used clinically as an antihypertensive agent and in scientific research to study the serotonin system; specifically, the 5-HT2 receptor family. It was discovered at Janssen Pharmaceutica in 1980. It is not available in the United States.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

<span class="mw-page-title-main">Dextromoramide</span> Chemical compound

Dextromoramide is a powerful opioid analgesic approximately three times more potent than morphine but shorter acting. It is subject to drug prohibition regimes, both internationally through UN treaties and by the criminal law of individual states, and is usually prescribed only in the Netherlands.

<span class="mw-page-title-main">Phenoperidine</span>

Phenoperidine(Operidine or Lealgin), is an opioid analgesic which is structurally related to pethidine and is used clinically as a general anesthetic.

<span class="mw-page-title-main">Fluspirilene</span> Chemical compound

Fluspirilene is a diphenylbutylpiperidine typical antipsychotic drug, used for the treatment of schizophrenia. It is administered intramuscularly. It was discovered at Janssen Pharmaceutica in 1963. A 2007 systematic review investigated the efficacy of fluspirilene decanoate for people with schizophrenia:

<span class="mw-page-title-main">Pipamperone</span> Antipsychotic drug

Pipamperone, also known as carpiperone and floropipamide or fluoropipamide, and as floropipamide hydrochloride (JAN), is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia and as a sleep aid for depression. It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan. Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.

<span class="mw-page-title-main">Piritramide</span> Synthetic opioid

Piritramide(R-3365, trade names Dipidolor, Piridolan, Pirium and others) is a synthetic opioid analgesic that is marketed in certain European countries including: Austria, Belgium, Czech Republic, Slovenia, Germany and the Netherlands. It comes in free form, is about 0.75x times as potent as morphine and is given parenterally for the treatment of severe pain. Nausea, vomiting, respiratory depression and constipation are believed to be less frequent with piritramide than with morphine, and it produces more rapid-onset analgesia when compared to morphine and pethidine. After intravenous administration the onset of analgesia is as little as 1–2 minutes, which may be related to its great lipophilicity. The analgesic and sedative effects of piritramide are believed to be potentiated with phenothiazines and its emetic (nausea/vomiting-inducing) effects are suppressed. The volume of distribution is 0.7-1 L/kg after a single dose, 4.7-6 L/kg after steady-state concentrations are achieved and up to 11.1 L/kg after prolonged dosing.

<span class="mw-page-title-main">Bezitramide</span> Chemical compound

Bezitramide is an opioid analgesic. Bezitramide itself is a prodrug which is readily hydrolyzed in the gastrointestinal tract to its active metabolite, despropionyl-bezitramide. Bezitramide was discovered at Janssen Pharmaceutica in 1961. It is most commonly marketed under the trade name Burgodin.

<span class="mw-page-title-main">Bromperidol</span> Chemical compound

Bromperidol, sold under the brand names Bromidol and Impromen among others, is a typical antipsychotic of the butyrophenone group which is used in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966. An ester prodrug, bromperidol decanoate, is a long-acting form of bromperidol used as a depot injectable.

Paul, Baron Stoffels is a Belgian MD, who studied medicine at the University of Hasselt and the University of Antwerp (UA). In addition he studied Infectious Diseases and Tropical Medicine at the Prince Leopold Institute of Tropical Medicine in Antwerp, Belgium. He is Chief Scientific Officier, Worldwide Chairman of Janssen pharmaceuticals and he is a member of the Johnson & Johnson Executive Committee.

<span class="mw-page-title-main">Rudi Pauwels</span>

Rudi Pauwels is a Belgian pharmacologist and biotech entrepreneur.

Didier R.G.G. de Chaffoy de Courcelles is a Belgian scientist and businessman. He was senior vice president of Drug Discovery Europe, and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica, until 2008 when he left the company.

Dr. Jan Constant Janssen was a Belgian physician and businessman. He was the third child of Adriaan Victor Janssen (1854–1942) and Anna Catharina Eelen (1855–1929). He went to high school in Hoogstraten and studied medicine at the Catholic University of Leuven and the University of Ghent. On 16 April 1925, he married Margriet Fleerackers, together they had four children. Their oldest son, Paul Janssen, would become one of the most successful scientists in pharmaceutics.

Joos Horsten (1942–2008) was a Belgian businessman. He founded Xian Janssen Pharmaceutical, the Sino-Belgian joint venture of Janssen Pharmaceutica, a Flemish pharmaceutical company in Belgium.

Paul J. Lewi was a Belgian scientist, who elaborated Spectral Map Analysis in 1975 and was one of the cofounders of chemometrics in 1983. Paul Lewi was married with Godelieve Debruyne and they have together 3 children and with Philomena Van Bylen, with 2 children.

Koen Andries is a Belgian Janssen Pharmaceutica scientist and professor at the University of Antwerp. In 2005 he and his team published a discovery about a new di-Aryl-Quinoline-based drug (R207910), now called bedaquiline, which promises a shorter and simpler treatment for drug resistant Tuberculosis (TB).

Paul Appermont is a Belgian businessman. Together with Joos Horsten, he laid the foundation of Xi'an Janssen Pharmaceutical. Appermont is a member of the board of EuropaBio.

The Dr. Paul Janssen Award for Biomedical Research is given annually by Johnson & Johnson to honor the work of an active scientist in academia, industry or a scientific institute in the field of biomedical research. It was established in 2004 and perpetuates the memory of Paul Janssen, the founder of Janssen Pharmaceutica, a Johnson & Johnson subsidiary.

<span class="mw-page-title-main">Clopenthixol</span> Antipsychotic medication

Clopenthixol (Sordinol), also known as clopentixol, is a typical antipsychotic drug of the thioxanthene class. It was introduced by Lundbeck in 1961.

References

  1. Paul Lewi, Obituary of Dr Paul Janssen (1926–2003), Drug Discovery Today, Volume 9, Issue 10, 15 May 2004, Pages 432–433
  2. Dr. Paul Janssen, 77, Dies; Founder of a Drug Company - website of the newspaper The New York Times
  3. Dr. Paul Janssen, 77; Founded International Pharmaceutical Firm - website of the newspaper LA Times
  4. I. Oransky, Paul Janssen, The Lancet, Volume 363, Issue 9404, Pages 251–251
  5. B. Granger, S. Albu, The Haloperidol Story, Annals of Clinical Psychiatry (after 1 January 2004), Volume 17, Number 3, Number 3/July–September 2005, pp. 137–140(4)
  6. Stanley TH, Egan TD, Van Aken H (2008). "A Tribute to Dr. Paul A. J. Janssen: Entrepreneur Extraordinaire, Innovative Scientist, and Significant Contributor to Anesthesiology" (PDF). Anesth Analg. 106 (2): 451–62. doi:10.1213/ane.0b013e3181605add. PMID   18227300. S2CID   20490363 . Retrieved 7 May 2011.
  7. Lopez-Munoz, Francisco; Alamo, Cecilio (2009). "The Consolidation of Neuroleptic Therapy: Janssen, the Discovery of Haloperidol and Its Introduction into Clinical Practice". Brain Research Bulletin. 79 (2): 130–141. doi:10.1016/j.brainresbull.2009.01.005. PMID   19186209. S2CID   7720401.
  8. "W. Royce Hawkins, M.D., John F. Zieglschmid, M.D., Clinical aspects of crew health". Lsda.jsc.nasa.gov. Archived from the original on 23 February 2012. Retrieved 12 March 2012.
  9. "Apollo Medical Kits". History.nasa.gov. Retrieved 12 March 2012.
  10. Magiels G, Paul Janssen. Pionier in farma en in China, Houtekiet, 2005
  11. molmo.be Archived 31 July 2009 at the Wayback Machine
  12. Yven Van Herrewege, Guido Vanham, Jo Michiels, Katrien Fransen, Luc Kestens, Koen Andries, Paul Janssen, and Paul Lewi, A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides, Antimicrob Agents Chemother. 2004 October; 48(10): 3684–3689
  13. "New AIDS Drug Discoveries To Battle Drug-Resistant HIV Strains". Sciencedaily.com. 20 August 2002. Retrieved 12 March 2012.
  14. Neuropsychopharmacology. "Thomas A Ban, Paul Adriaan Jan Janssen, 1926–2003, Neuropsychopharmacology (2004) 29, 1579–1580". Nature.com. Retrieved 12 March 2012.
  15. "De Grootste Belg". De Standaard (in Dutch). Retrieved 4 October 2011.
  16. "Most Important Belgian Scientist". Picture.belga.be. 22 October 2008. Archived from the original on 20 February 2012. Retrieved 12 March 2012.

Further reading